VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2017 | Novel agents in multiple myeloma: considering toxicity and side effects

We’ve seen a number of approvals in multiple myeloma over the past year. Enrique M. Ocio, MD, PhD, from the University of Salamanca,
Salmanca, Spain discusses the results from recent studies presented at the European Hematology Association (EHA) 2017 meeting, as well as the novel adverse events and toxicities that these new drugs can cause.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter